ADULTS & ADOLESCENTS AGED 12+ YEARS

DUPIXENT demonstrated greater histologic improvements compared to placebo at Week 24.1,3

Histologic Remissiona
  • Part A: 60% of patients with DUPIXENT (n=42) vs 5% with placebo (n=39) (P<0.001)
  • Part B: 59% of patients with DUPIXENT (n=80) vs 6% with placebo (n=79) (P<0.001)
Histologic Responseb
  • Part A: 64% of patients with DUPIXENT (n=42) vs 8% with placebo (n=39)
  • Part B: 83% of patients with DUPIXENT (n=80) vs 8% with placebo (n=79)

Histologic improvements were observed at Week 52 with continued weekly DUPIXENT treatment.3

Histologic Remissiona
  • Part A-C: 56% of patients after 52 weeks of treatment with DUPIXENT (n=34) and 60% after switching to DUPIXENT from placebo at Week 24 (n=30)
  • Part B-C: 85% of patients after 52 weeks of treatment with DUPIXENT (n=74) and 68% after switching to DUPIXENT from placebo at Week 24 (n=37)
Histologic Responseb
  • Part A-C: 82% of patients after 52 weeks of treatment with DUPIXENT (n=34) and 70% after switching to DUPIXENT from placebo at Week 24 (n=30)
  • Part B-C: 100% of patients after 52 weeks of treatment with DUPIXENT (n=74) and 78% after switching to DUPIXENT from placebo at Week 24 (n=37)

Results are descriptive in the extended active treatment period at Week 52. Definitive conclusions cannot be made due to limitations associated with extended active treatment design, including lack of comparator arm and decreasing sample size.3

aCoprimary endpoint at Week 24;
secondary endpoint at Week 52.1,3

bSecondary endpoint at Weeks 24 and 52. In Part B, this endpoint was ordered after the point at which hierarchical testing procedure failed; results are descriptive.3

To be eligible to participate in the study, all participants must have had uncontrolled EoE as defined by ≥15 intraepithelial EOS/HPF despite an 8-week course of a high-dose PPI and a Dysphagia Symptom Questionnaire (DSQ) score of ≥10.1,4

CHILDREN AGED 1-11 YEARS

DUPIXENT demonstrated greater histologic improvements compared to placebo at Week 16.1,3

Histologic improvements were defined as the proportion of participants who achieved peak esophageal intraepithelial eosinophil counts of <15 EOS/HPF (histologic response) or ≤6 EOS/HPF (histologic remission).1

Histologic Remissionc
  • EoE KIDS-Part A: 66% of patients with DUPIXENT (n=32) vs 3% with placebo (n=29) (P<0.0001)
Histologic Responsed
  • EoE KIDS-Part A: 81% of patients with DUPIXENT (n=32) vs 3% with placebo (n=29) (P<0.0001)

Histologic responses were maintained at Week 52 with continued DUPIXENT treatment.3

Histologic Remissionc
  • EoE KIDS-Part B: 53% of patients with DUPIXENT (n=32) and 53% after switching to DUPIXENT at Week 16 (n=15)
Histologic Responsed
  • EoE KIDS-Part B: 78% of patients with DUPIXENT (n=32) and 67% after switching to DUPIXENT at Week 16 (n=15)

Results are descriptive in the extended active treatment period at Week 52. Definitive conclusions cannot be made due to limitations associated with extended active treatment design, including lack of comparator arm and decreasing sample size.3

cPrimary endpoint at Week 16; secondary endpoint at Week 52.3

dSecondary endpoint at Weeks 16 and 52.3

To be eligible to participate in the study, all participants must have had uncontrolled EoE as defined by ≥15 intraepithelial EOS/HPF despite an 8-week course of a high-dose PPI and a history of EoE signs and symptoms.1,3

VIEW THE HISTOLOGIC RESULTS IN ADULTS & ADOLESCENTS (12+ YEARS)
VIEW THE HISTOLOGIC RESULTS IN CHILDREN (1-11 YEARS)